10.27.22
Ingredient supplier DolCas Biotech, LLC has gained two natural product licenses from Health Canada for its concentrated turmeric extract, Curcugen, and for its powdered ginger extract, Ginfort. The two ingredient brands are backed by studies for safety and clinical efficacy and are solely distributed by DolCas.
Citing market research from Mordor Intelligence, DolCas reports that the Canadian nutraceuticals market is anticipated to witness a CAGR of 5.62% from 2022-2027. The market researcher also indicated that personal nutrition is a current trend of interest for consumers, and that the regulatory environment for dietary supplements in Canada is one of the biggest issues faced by nutraceutical companies.
The first license, on Curcugen, supports the health benefits of antioxidants called curcuminoids. The formulation of curcuminoids is natively complexed to other naturally-occurring turmeric constituents in a turmeric oleoresin matrix, which is done to improve bioavailability. Curcugen has been the subject of three clinical studies which support its role in exercise recovery, healthy digestion, mood, and joint comfort. It is presently the subject of a clinical study evaluating its role in fatigue, cognitive performance, and mood. Earlier this year, Curcugen was also recognized as a food supplement in several European countries, allowing regulated use of the brand in its most common clinical dose of 500 mg/day.
The second patent supports Ginfort as a digestive health ingredient. Ginfort delivers gingeroid compounds at a concentration of 26%, including both gingerols and shogoals. The ingredient is formulated to stabilize the volatile gingerols in order to maintain the ratio between the bioactive types over time, as the powdered oleoresin base material provides a slow, sustained release of the gingeroids from its matrix.
Ginfort’s efficacy is supported by two clinical studies, one of which found significant digestive health benefits, and the second of which investigated the ingredient’s ability to relieve menstrual discomfort in healthy, reproductive-age women.
The Health Canada approved claims include: “Help(s) prevent nausea and vomiting associated with motion sickness and/or seasickness” while also allowing broader digestive support claims informed by traditional medicine use. The monograph for ginger permits the added claims language to parallel, “Traditionally used in Herbal Medicine to help relieve digestive upset/disturbances including lack of appetite, nausea, digestive spasms, indigestion, dyspepsia and flatulent colic (carminative);” “For use as a digestive support active;” and, for its role in respiratory support, “Traditionally used in Herbal Medicine as an expectorant and cough suppressant (antitussive) to help relieve bronchitis as well as coughs and colds.”
“DolCas already is in discussion with several finished product makers and private label companies interested in these brands,” said Dr. Shavon Jackson-Michel, director of medical and scientific affairs. “We already have an office and sales support team in Canada to help companies seeking to include powerful antioxidant and digestive support ingredients such as these in their product line.”
Citing market research from Mordor Intelligence, DolCas reports that the Canadian nutraceuticals market is anticipated to witness a CAGR of 5.62% from 2022-2027. The market researcher also indicated that personal nutrition is a current trend of interest for consumers, and that the regulatory environment for dietary supplements in Canada is one of the biggest issues faced by nutraceutical companies.
The first license, on Curcugen, supports the health benefits of antioxidants called curcuminoids. The formulation of curcuminoids is natively complexed to other naturally-occurring turmeric constituents in a turmeric oleoresin matrix, which is done to improve bioavailability. Curcugen has been the subject of three clinical studies which support its role in exercise recovery, healthy digestion, mood, and joint comfort. It is presently the subject of a clinical study evaluating its role in fatigue, cognitive performance, and mood. Earlier this year, Curcugen was also recognized as a food supplement in several European countries, allowing regulated use of the brand in its most common clinical dose of 500 mg/day.
The second patent supports Ginfort as a digestive health ingredient. Ginfort delivers gingeroid compounds at a concentration of 26%, including both gingerols and shogoals. The ingredient is formulated to stabilize the volatile gingerols in order to maintain the ratio between the bioactive types over time, as the powdered oleoresin base material provides a slow, sustained release of the gingeroids from its matrix.
Ginfort’s efficacy is supported by two clinical studies, one of which found significant digestive health benefits, and the second of which investigated the ingredient’s ability to relieve menstrual discomfort in healthy, reproductive-age women.
The Health Canada approved claims include: “Help(s) prevent nausea and vomiting associated with motion sickness and/or seasickness” while also allowing broader digestive support claims informed by traditional medicine use. The monograph for ginger permits the added claims language to parallel, “Traditionally used in Herbal Medicine to help relieve digestive upset/disturbances including lack of appetite, nausea, digestive spasms, indigestion, dyspepsia and flatulent colic (carminative);” “For use as a digestive support active;” and, for its role in respiratory support, “Traditionally used in Herbal Medicine as an expectorant and cough suppressant (antitussive) to help relieve bronchitis as well as coughs and colds.”
“DolCas already is in discussion with several finished product makers and private label companies interested in these brands,” said Dr. Shavon Jackson-Michel, director of medical and scientific affairs. “We already have an office and sales support team in Canada to help companies seeking to include powerful antioxidant and digestive support ingredients such as these in their product line.”
